West Pharma Crushes Q1 2026, Raises Guidance

West Pharmaceutical Services exceeded Wall Street expectations in Q1 2026 with revenue of $844.9 million, a 21% increase from last year, and adjusted EPS of $2.13, beating the consensus by 27%. Strong demand for high-value product components, particularly in GLP-1 therapies and biologics, drove the results. Operational improvements boosted output and margins to 21% from 15.3% last year. Management raised full-year revenue guidance to $3.32 billion and adjusted EPS to $8.58, up nearly 7%. They anticipate low double-digit growth in premium components, biologics momentum, and efficiency gains to maintain margin growth. However, they are monitoring macro risks like supply chain issues and commodity prices. The stock surged from $274 to $312 post-earnings, reflecting investor confidence. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/50d7253d775c49f0